Eterna Therapeutics Inc (ERNA)

Feb 06, 2025

ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 06, 2025

Feb 06, 2025

Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News

Feb 06, 2025

Feb 05, 2025

Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World

Feb 05, 2025

Feb 04, 2025

Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex

Feb 04, 2025

Feb 02, 2025

StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Feb 02, 2025

Jan 30, 2025

Eterna Therapeutics expands scientific board with oncology experts - MSN

Jan 30, 2025

Jan 30, 2025

Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL

Jan 30, 2025

Jan 28, 2025

Eterna Therapeutics expands scientific board with oncology experts By Investing.com - Investing.com Canada

Jan 28, 2025

Jan 28, 2025

Eterna Therapeutics Announces Expansion of Scientific Advisory Board - GlobeNewswire

Jan 28, 2025

Jan 17, 2025

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Jan 17, 2025

Jan 16, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 16, 2025

Jan 16, 2025

3 Penny Stocks to Watch Now, 1/16/25 - TipRanks

Jan 16, 2025

Jan 15, 2025

What Did We Note About Insider Trading At Meiwu Technology Company Ltd (NASDAQ: WNW)? - Stocks Register

Jan 15, 2025

Jan 15, 2025

ERNA-101 extends survival in mice with ovarian cancer - BioWorld Online

Jan 15, 2025

Jan 14, 2025

Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn

Jan 14, 2025

Jan 14, 2025

Wall Street Climbs as Producer Inflation Report Offers Relief to Investors – Market - HPBL

Jan 14, 2025

Jan 14, 2025

Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn

Jan 14, 2025

Jan 14, 2025

Eterna Therapeutics reports breakthrough in ovarian cancer treatment - Investing.com

Jan 14, 2025

Jan 14, 2025

Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites - The Manila Times

Jan 14, 2025

Jan 14, 2025

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer - Yahoo Finance

Jan 14, 2025

Jan 13, 2025

Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com

Jan 13, 2025

Jan 10, 2025

Eterna Therapeutics Faces Nasdaq Compliance and Board Changes - TipRanks

Jan 10, 2025

Jan 09, 2025

Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer - The Manila Times

Jan 09, 2025

Jan 09, 2025

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors - Yahoo Finance

Jan 09, 2025

Jan 09, 2025

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World

Jan 09, 2025

Jan 08, 2025

Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion Landscape - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

Eterna Therapeutics Inc. Announces Appointment of Dr. Elena Ratner to Board of Directors - Marketscreener.com

Jan 08, 2025

Jan 07, 2025

Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Jan 07, 2025

Jan 06, 2025

Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India

Jan 06, 2025

Jan 03, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 03, 2025

Jan 01, 2025

StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Jan 01, 2025

Dec 24, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World

Dec 24, 2024

Dec 18, 2024

ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada

Dec 18, 2024

Dec 14, 2024

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance

Dec 14, 2024

Dec 11, 2024

Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online

Dec 11, 2024

Dec 04, 2024

Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online

Dec 04, 2024

Dec 04, 2024

Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada

Dec 04, 2024

Dec 03, 2024

Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire

Dec 03, 2024

Dec 03, 2024

Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan

Dec 03, 2024

Dec 02, 2024

ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia

Dec 02, 2024

Nov 26, 2024

Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa

Nov 26, 2024